A Trial of ZD1839 (Iressa) in Patients With Advanced Renal Cell Carcinoma
OBJECTIVES: I. Determine the efficacy of ZD 1839 in patients with metastatic renal cell
cancer. II. Determine the time to disease progression in patients treated with this drug.
III. Determine the safety of this drug in these patients.
OUTLINE: Patients receive oral ZD 1839 once daily. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity. Patients are followed for at least
PROJECTED ACCRUAL: A total of 16-46 patients will be accrued for this study within 1 year.
Primary Purpose: Treatment
Robert J. Motzer, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|